Next Article in Journal
Prevalence of Non-B HIV-1 Subtypes in North Italy and Analysis of Transmission Clusters Based on Sequence Data Analysis
Previous Article in Journal
VelA and LaeA are Key Regulators of Epichloë festucae Transcriptomic Response during Symbiosis with Perennial Ryegrass
Article

Curative Treatment of Candidiasis by the Live Biotherapeutic Microorganism Lactobacillus rhamnosus Lcr35® in the Invertebrate Model Caenorhabditis elegans: First Mechanistic Insights

1
Université Clermont Auvergne, INRAE, VetAgro Sup, UMRF, 15000 Aurillac, France
2
Biose Industrie, 24 avenue Georges Pompidou, 15000 Aurillac, France
*
Author to whom correspondence should be addressed.
Microorganisms 2020, 8(1), 34; https://doi.org/10.3390/microorganisms8010034
Received: 7 November 2019 / Revised: 16 December 2019 / Accepted: 20 December 2019 / Published: 23 December 2019
(This article belongs to the Section Molecular Microbiology and Immunology)
The resistance of Candida albicans to conventional drug treatments, as well as the recurrence phenomena due to dysbiosis caused by antifungal treatments, have highlighted the need to implement new therapeutic methodologies. The antifungal potential of live biotherapeutic products (LBP) has already been demonstrated using preclinical models (cell cultures, laboratory animals). Understanding their mechanisms of action is strategic for the development of new therapeutics for humans. In this study, we investigated the curative anti-C. albicans properties of Lactobacillus rhamnosus Lcr35® using the in vitro Caco-2 cell and the in vivo Caenorhabditis elegans models. We showed that Lcr35® does inhibit neither the growth (p = 0.603) nor the biofilm formation (p = 0.869) of C. albicans in vitro. Lcr35® protects the animal from the fungal infection (+225% of survival, p < 2 × 10–16) even if the yeast is detectable in its intestine. In contrast, the Lcr35® cell-free supernatant does not appear to have any antipathogenic effect. At the mechanistic level, the DAF-16/Forkhead Box O transcription factor is activated by Lcr35® and genes of the p38 MAP Kinase signaling pathway and genes involved in the antifungal response are upregulated in presence of Lcr35® after C. albicans infection. These results suggest that the LBM strain acts by stimulating its host via DAF-16 and the p38 MAPK pathway. View Full-Text
Keywords: Lactobacillus rhamnosus Lcr35®; Candida albicans; Caenorhabditis elegans; curative treatment; immune response Lactobacillus rhamnosus Lcr35®; Candida albicans; Caenorhabditis elegans; curative treatment; immune response
Show Figures

Figure 1

MDPI and ACS Style

Poupet, C.; Veisseire, P.; Bonnet, M.; Camarès, O.; Gachinat, M.; Dausset, C.; Chassard, C.; Nivoliez, A.; Bornes, S. Curative Treatment of Candidiasis by the Live Biotherapeutic Microorganism Lactobacillus rhamnosus Lcr35® in the Invertebrate Model Caenorhabditis elegans: First Mechanistic Insights. Microorganisms 2020, 8, 34. https://doi.org/10.3390/microorganisms8010034

AMA Style

Poupet C, Veisseire P, Bonnet M, Camarès O, Gachinat M, Dausset C, Chassard C, Nivoliez A, Bornes S. Curative Treatment of Candidiasis by the Live Biotherapeutic Microorganism Lactobacillus rhamnosus Lcr35® in the Invertebrate Model Caenorhabditis elegans: First Mechanistic Insights. Microorganisms. 2020; 8(1):34. https://doi.org/10.3390/microorganisms8010034

Chicago/Turabian Style

Poupet, Cyril, Philippe Veisseire, Muriel Bonnet, Olivier Camarès, Marylise Gachinat, Caroline Dausset, Christophe Chassard, Adrien Nivoliez, and Stéphanie Bornes. 2020. "Curative Treatment of Candidiasis by the Live Biotherapeutic Microorganism Lactobacillus rhamnosus Lcr35® in the Invertebrate Model Caenorhabditis elegans: First Mechanistic Insights" Microorganisms 8, no. 1: 34. https://doi.org/10.3390/microorganisms8010034

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop